1	Prevalence and characteristics of <i>Plasmodium vivax</i> Gametocytes in
2	Duffy-positive and Duffy-negative populations across Ethiopia
3	
4	Ebony Little <sup>1*</sup> , Tassew T. Shenkutie <sup>2,3*</sup> , Meshesha Tsigie Negash <sup>4</sup> , Beka R. Abagero <sup>5</sup> , Abnet
5	Abebe <sup>4</sup> , Jean Popovici <sup>6</sup> , Sindew Mekasha <sup>4</sup> , Eugenia Lo <sup>1,2</sup>
6	
7	*Co-first authors with equal contributions
8	
9	<sup>1</sup> Department of Biological Sciences, University of North Carolina at Charlotte, North Carolina,
10	USA; <sup>2</sup> Department of Microbiology and Immunology, Drexel University, College of Medicine,
11	Philadelphia, PA, USA; <sup>3</sup> Department of Medical Laboratory Sciences, Debre Brehan University,
12	Debre Brehan, Ethiopia; <sup>4</sup> Ethiopian Public Health Institute, Addis Ababa, Ethiopia; <sup>5</sup> Department
13	of Molecular and Cellular Biology and Genetics, Drexel University, College of Medicine,
14	Philadelphia, PA, USA; <sup>6</sup> Institute Pasteur in Cambodia, Phnom Penh, Cambodia;
15	
16	Corresponding author: Eugenia Lo; e-mail: el855@drexel.edu
17 18	Abstract: Plasmodium parasites replicate asexually in the human host. The proportion of
19	infections that carries gametocytes is a proxy for human-to-mosquito transmissibility. It is
20	unclear what proportion of <i>P. vivax</i> infections in Duffy-negatives carries gametocytes. This study
21	aims to determine the prevalence of <i>P. vivax</i> in Duffy-negatives across broad regions of Ethiopia
22	and characterize parasite stages. Finger-prick blood samples were collected for microscopic and
23	molecular screening of <i>Plasmodium</i> parasites and Duffy status of individuals. Molecular

It is made available under a CC-BY-NC-ND 4.0 International license .

24	screening of plasmodium species and Duffy blood group genotyping was done using SYBR
25	green and Taqman qPCR method. Among the total 447 samples, 414 (92.6%) were P. vivax
26	confirmed and, 16 (3.9%) of them were from Duffy-negatives. Of these, 5/16 (31.3%) Duffy-
27	negative P. vivax-infected samples were detected with gametocytes. Of the 398 Duffy-positive
28	P. vivax-infected samples, 150 (37.7%) were detected with gametocytes, slightly higher than that
29	in Duffy-negatives. This study highlights the presence of <i>P. vivax</i> gametocytes in Duffy-negative
30	infections, suggestive of human-to-mosquito transmissibility. Although P. vivax infections in
31	Duffy-negatives are commonly associated with low parasitemia, some of these infections were
32	shown with relatively high parasitemia and may represent better erythrocyte invasion capability
33	of P. vivax and hidden reservoirs that can contribute to transmission. A better understanding of
34	P. vivax transmission biology and gametocyte function particularly in Duffy-negative
35	populations would aid future treatment and management of vivax malaria in Africa
36	Keywords: Plasmodium vivax, Duffy-negatives, Malaria transmission, Gametocytes, Ethiopia
37	Running title: Plasmodium vivax gametocyte in Duffy-negative population

## 38 Introduction

Yearly, there are about 619,000 malaria-related deaths and ~247 million malaria cases 39 reported globally.<sup>1</sup> Out of the five malaria *Plasmodium* species, *P. vivax* is the most widespread.<sup>2</sup> 40 41 Duffy negative individuals were thought to be resistant to *P. vivax*. However, a growing number of *P. vivax* cases reported throughout Africa where Duffy-negative individuals predominate,<sup>3</sup> 42 demonstrated that *P. vivax* can infect Duffy-negative individuals<sup>4,5</sup> and could potentially spread 43 and transmit across populations.<sup>5,6</sup> Due to epidemiological and ethnic differences, the prevalence 44 of *P. vivax* in Duffy-negative individuals varies across Africa.<sup>4</sup> Considering *P. vivax* can infect 45 46 and adapt to Duffy-negative individuals, it is possible that these infections can produce

It is made available under a CC-BY-NC-ND 4.0 International license .

gametocytes leading to transmission.<sup>7</sup> The extent of transmission may vary by environmental and
host factors.<sup>8</sup>

49 During the *Plasmodium* life cycle, the parasites undergo multiple asexual replicative 50 cycles in the human host, and in each erythrocytic replication cycle, a small portion ( $\Box 0.1\%$ -5%) 51 of the asexual stages develops into sexual gametocytes. The proportion of infections that carries gametocytes is a proxy for human-to-mosquito transmissibility.<sup>9</sup> Within the mosquito's midgut, 52 male and female gametocytes undertake gametogenesis.<sup>10</sup> After the gametes have fertilized, a 53 54 zygote is created, which later transforms into a motile ookinete. Under the basal lamina, ookinetes form an oocyst by crossing the midgut epithelium.<sup>10,11</sup> Numerous thousands of 55 56 sporozoites develop in the oocyst, and as the oocyst wall ruptures, sporozoites enter the 57 hemolymph and infect the salivary gland. The intricate life cycle of the parasite is then completed when sporozoites are inoculated into another person through mosquito bites.<sup>12</sup> 58 59 Gametocytogenesis is influenced by epigenetic, ecological, and heritable factors associated with the parasite.<sup>13</sup> The occurrence of gametocytogenesis is also influenced by factors associated with 60 human hosts such as immunity status, antimalaria drug treatment and genetic factors.<sup>14,15</sup> 61 62 The distribution of *P. vivax* in Duffy-negatives across Ethiopia as well as the parasite 63 stages of these infections remain largely unclear. The presence of gametocytes in symptomatic or 64 asymptomatic individuals can lead to onward transmission in the communities. Knowledge of

gametocyte reservoirs allows for prioritizing transmission blocking vaccines against *P. vivax* in
Africa.<sup>16,17</sup> This study aims to 1) compare the distribution of *P. vivax* in Duffy-positive and
Duffy-negative across Ethiopia; 2) determine the different stages of *P. vivax* in Duffy-positive
and Duffy-negative infections; and 3) examine demographic and clinical features of Duffy-

It is made available under a CC-BY-NC-ND 4.0 International license .

69 negative *P. vivax* infections. These findings will advance current knowledge of *vivax* malaria

- 70 distribution and transmission in Africa.
- 71

## 72 Material & Methods

73 Study sites

74 A total of 447 febrile patient samples were collected in twenty-seven (27) health facilities from seven major regions of Ethiopia including Afar, Amhara, Benishangul/Gumuz, Gambella, 75 76 Oromia, Sidama, and Southern Nations Nationalities and People's Region (SNNPR) (Figure 1) 77 from 2020-2021. These seven regions also vary in elevation: Afar is in the northeastern part of the country with altitude 379 m (Lat, Long: 11.568, 41.438),<sup>18</sup> Amhara is in the north with 78 altitude 1268 m (Lat, Long: 11.66334, 338.821903),<sup>19</sup> Gambella is in the west bordering Sudan 79 with altitude 447 m (Lat, Long: 8.24999, 34.5833),<sup>20</sup> Oromia is in the east with altitude 959 m 80 (Lat, Long: 7.98906, 39.38118).<sup>21</sup> Sidama is in the southeast with altitude 1742 m (Lat, Long: 81  $(6.7372.38.4008)^{22}$  and the SNNPR is in the south with altitude 1200 m (Lat. Long: 6.05862). 82 36.7273).<sup>23</sup> 83

Figure 1. A map showing the study sites in Ethiopia with malaria incidence ranges from high in
the western part to low in the eastern part of the country. These sites represent seven major
regions including Afar, Amhara, Benishangul/Gumuz, Gambella, Oromia, Sidama, and Southern
Nations, Nationalities, and People's Region (SNNPR) with diverse ethnic groups.

88

## 89 Blood sample collection and microscopic examination

90 Finger-prick blood samples were collected from individuals with at least two clinical
91 symptoms, had been suspected for malaria infection and visiting health facilities for malaria
92 diagnosis. All samples were selectively collected from *P. vivax* microscopic confirmed patients.

It is made available under a CC-BY-NC-ND 4.0 International license .

93 As soon as possible, the DBS samples were also done at the site of the sample collection for 94 further molecular screening of plasmodium species. The thick and thin blood films were 95 prepared for microscopic screening of *Plasmodium* parasites. Blood smears were stained for 10 96 minutes with 10% Giemsa staining solution (pH 7.2). The parasite species, the developmental 97 stages of the parasites, and the density of asexual parasites and sexual gametocytes were 98 examined by microscopy. A minimum of 200 microscopic fields were examined at a 99 magnification of 1,000X using oil immersion optics before a slide was declared negative for 100 malaria parasites by the light microscope. Parasitemia/µl of blood was estimated from the thick 101 films as follows: the number of parasites per 200 white blood cells was multiplied by 8,000 (an 102 average white blood cell count/µl) and then divided by 200. Slides were read twice by the 103 primary readers at the site of the study and the secondary readers at EPHI. Discordant results 104 were confirmed by a third slide expert microscope readers. Final species diagnosis was decided by the expert readers. Rapid diagnostic test (RDT) was also conducted for malaria detection.<sup>24,25</sup> 105 106

#### 107 Molecular screening of *Plasmodium species*

108 Parasite DNA was isolated from a dried blood spot using the Saponin/Chelex method.<sup>26</sup> *P. vivax* and *P. falciparum* were detected by the SYBR Green qPCR detection method<sup>2</sup> using the 109 110 published primers (forward: 5'-GAATTTTCTCTTCGGAGTTTATTCTTAGATTGC-3'; reverse: 5'-GCCGCAAGCTCCACGCCTGGTGGTGC-3') specific to P.  $vivax^{27,28}$  and P. 111 falciparum 18S rRNA (forward: 5'-AGTCATCTTTCGAGGTGACTTTTAGATTGCT-3'; 112 reverse: 5'-GCCGCAAGCTCCACGCCTGGTGGTGC-3').<sup>29</sup> Amplification was conducted in a 113 114 20 µl reaction mixture containing 2 µl of genomic DNA, 10 µl SYBR Green qPCR Master Mix 115 (Thermo Scientific), and 0.5 uM primer. The reactions were performed in QuantStudio Real-

It is made available under a CC-BY-NC-ND 4.0 International license .

116 Time PCR Detection System (Thermo Fisher), with an initial denaturation at 95°C for 3 min, 117 followed by 45 cycles at 94°C for 30 sec, 55°C for 30 sec, and 68°C for 1 min with a final 95°C 118 for 10 sec. This was followed by a melting curve step of temperature ranging from 65°C to 95°C 119 with  $0.5^{\circ}$ C increments to determine the melting temperature of each amplified product. Each 120 assay included positive controls of P. vivax Pakchong (MRA-342G) and Nicaragua (MRA-121 340G) isolates, P. falciparum isolates 7G8 (MRA-926) and HB3 (MRA-155), in addition to 122 negative controls including uninfected samples and water. A standard curve was produced from a 123 ten-fold dilution series of the *P. vivax* and *P. falciparum* control plasmid to determine the 124 amplification efficiency of the qPCR. Melting curve analyses were performed for each amplified 125 sample to confirm specific amplifications of the target sequence. The slope of the linear 126 regression of threshold cycle number (Ct) versus log10 (gene copy number) was used to 127 calculate amplification efficiency of each plate run based on internal standard controls. For the 128 measure of reproducibility of the threshold cycle number, the mean Ct value and standard error 129 was calculated from three independent assays of each sample. A cut-off threshold of 0.02 130 fluorescence units that robustly represented the threshold cycle at the log-linear phase of the 131 amplification and above the background noise was set to determine Ct value for each assay. 132 Samples yielding Ct values higher than 40 (as indicated in the negative controls) were considered 133 negative for *Plasmodium* species. Parasite density in a sample was quantified by converting the Ct values into gene copy number (GCN) using the following equation:  $GCN_{sample} = 2^{E \times (40-2)}$ 134 <sup>Ctsample)</sup>: where GCN stands for gene copy number, *Ct* for the threshold cycle of the sample, and E 135 136 for amplification efficiency. The differences in the log-transformed parasite GCN between samples among the study sites were assessed for significance at the level of 0.05.<sup>30,31</sup> 137

138

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 139 **Duffy blood group genotyping**

- 140 For all DBS samples, we employed qPCR-based TaqMan assay to examine the point
- 141 mutation (c.1-67T>C; rs2814778) in the GATA-1 transcription factor binding site of the DARC
- 142 gene. The following primers (forward: 5'-GGCCTGAGGCTTGTGCAGGCAG-3'; reverse: 5'-
- 143 CATACTCACCCTGTGCAGACAG-3') and dye-labeled probes (FAM-
- 144 CCTTGGCTCTTA[C]CTTGGAAGCACAGG-BHQ; HEX-
- 145 CCTTGGCTCTTA[*T*]CTTGGAAGCACAGG-BHQ) were used. Each PCR contained 5µl
- 146 TaqMan Fast Advanced Master mix (Thermo), 1µl DNA template, and 0.5µl of each primer
- 147 (10nM), and 0.5µl of each probe (10nM). The reactions were performed with an initial
- 148 denaturation at 95°C for 2 min, followed by 45 cycles at 95°C for 3 sec and 58°C for 30 sec. A
- 149 no-template control was used in each assay. The *Fy* genotypes were determined by the allelic
- 150 discrimination plot based on the fluorescent signal emitted from the allele-specific probes. For *P*.
- *vivax* positive samples, a 1,100-bp fragment of the *DARC* gene was further amplified using
- 152 previously published primers.<sup>3</sup> Each PCR contained 20µl DreamTaq PCR Mastermix, 1µl DNA
- 153 template, and 0.5μl each primer. PCR conditions were 94°C for 2-min, followed by 35 cycles of
- 154 94°C for 20s, 58°C for 30s, and 68°C for 60s, followed by a 4-min extension. PCR products
- 155 were purified, and Sanger sequenced. Chromatograms were visually inspected to determine and
- 156 confirm the Fy genotypes based on the TaqMan assays.<sup>31</sup>
- 157

#### 158 Statistical analyses

159 SPSS version 21.0 was used for analyzing the socio-demographic information of the 160 participants using descriptive statistics. To test the association between malaria infection and 161 factors including gender, age, ethnicity, and clinical symptoms, bivariate and multivariate

162	logistic regression was performed. The odds ratio and associated 95% confidence interval (CI)
163	were computed to assess the strength of association. P-values under 0.05 were considered as
164	significant.
165	
166	Ethics statement
167	Scientific and ethical clearance was obtained from the institutional scientific and ethical
168	review boards of Ethiopian Public Health Institute, Ethiopia and Drexel University, USA.
169	Written informed consent/assent for study participation was obtained from all participants of the
170	study and parents/guardians (for minors under 18 years old).
171	
172	Results
173	Socio-demographic characteristics of study participants
174	For the 447 study participants, the age ranged from 6 months to 70 years old. The mean
1/1	
175	age was 20.87; and 269 (60.1%) of the respondents were males and 171 (38.2%) were females.
175 176	age was 20.87; and 269 (60.1%) of the respondents were males and 171 (38.2%) were females. The greatest proportion of the samples were from SNNPR (34.8%) followed by Oromia (31.3%)
175 176 177	age was 20.87; and 269 (60.1%) of the respondents were males and 171 (38.2%) were females. The greatest proportion of the samples were from SNNPR (34.8%) followed by Oromia (31.3%) and Amhara (23.9%). Afar (1.1%) and Sidama (0.4%) had the smallest sample size ( <b>Table 1</b> ).
175 175 176 177 178	age was 20.87; and 269 (60.1%) of the respondents were males and 171 (38.2%) were females. The greatest proportion of the samples were from SNNPR (34.8%) followed by Oromia (31.3%) and Amhara (23.9%). Afar (1.1%) and Sidama (0.4%) had the smallest sample size ( <b>Table 1</b> ). <b>Table 1.</b> Socio-demographic characteristics of the study participants in seven regional states
175 176 177 178 179	age was 20.87; and 269 (60.1%) of the respondents were males and 171 (38.2%) were females. The greatest proportion of the samples were from SNNPR (34.8%) followed by Oromia (31.3%) and Amhara (23.9%). Afar (1.1%) and Sidama (0.4%) had the smallest sample size ( <b>Table 1</b> ). <b>Table 1.</b> Socio-demographic characteristics of the study participants in seven regional states across Ethiopia.
175 176 177 178 179 180	age was 20.87; and 269 (60.1%) of the respondents were males and 171 (38.2%) were females. The greatest proportion of the samples were from SNNPR (34.8%) followed by Oromia (31.3%) and Amhara (23.9%). Afar (1.1%) and Sidama (0.4%) had the smallest sample size ( <b>Table 1</b> ). <b>Table 1.</b> Socio-demographic characteristics of the study participants in seven regional states across Ethiopia.
175 176 177 178 179 180 181	age was 20.87; and 269 (60.1%) of the respondents were males and 171 (38.2%) were females. The greatest proportion of the samples were from SNNPR (34.8%) followed by Oromia (31.3%) and Amhara (23.9%). Afar (1.1%) and Sidama (0.4%) had the smallest sample size ( <b>Table 1</b> ). <b>Table 1.</b> Socio-demographic characteristics of the study participants in seven regional states across Ethiopia. Distribution of the Duffy genotypes and prevalence of gametocyte across Ethiopia
175 176 177 178 179 180 181 182	<ul> <li>age was 20.87; and 269 (60.1%) of the respondents were males and 171 (38.2%) were females.</li> <li>The greatest proportion of the samples were from SNNPR (34.8%) followed by Oromia (31.3%)</li> <li>and Amhara (23.9%). Afar (1.1%) and Sidama (0.4%) had the smallest sample size (<b>Table 1</b>).</li> <li><b>Table 1.</b> Socio-demographic characteristics of the study participants in seven regional states across Ethiopia.</li> <li><b>Distribution of the Duffy genotypes and prevalence of gametocyte across Ethiopia</b></li> <li>Of the 447 study participants, 422 (94.4%) were confirmed with <i>Plasmodium</i> infections.</li> </ul>
<ol> <li>175</li> <li>176</li> <li>177</li> <li>178</li> <li>179</li> <li>180</li> <li>181</li> <li>182</li> <li>183</li> </ol>	<ul> <li>age was 20.87; and 269 (60.1%) of the respondents were males and 171 (38.2%) were females.</li> <li>The greatest proportion of the samples were from SNNPR (34.8%) followed by Oromia (31.3%)</li> <li>and Amhara (23.9%). Afar (1.1%) and Sidama (0.4%) had the smallest sample size (<b>Table 1</b>).</li> <li><b>Table 1.</b> Socio-demographic characteristics of the study participants in seven regional states across Ethiopia.</li> <li><b>Distribution of the Duffy genotypes and prevalence of gametocyte across Ethiopia</b></li> <li>Of the 447 study participants, 422 (94.4%) were confirmed with <i>Plasmodium</i> infections.</li> <li>About 72% of the cases were <i>P. vivax</i> infection (322 out of 447), 1.8% were <i>P. falciparum</i></li> </ul>
<ol> <li>175</li> <li>176</li> <li>177</li> <li>178</li> <li>179</li> <li>180</li> <li>181</li> <li>182</li> <li>183</li> <li>184</li> </ol>	<ul> <li>age was 20.87; and 269 (60.1%) of the respondents were males and 171 (38.2%) were females.</li> <li>The greatest proportion of the samples were from SNNPR (34.8%) followed by Oromia (31.3%) and Amhara (23.9%). Afar (1.1%) and Sidama (0.4%) had the smallest sample size (<b>Table 1</b>).</li> <li><b>Table 1.</b> Socio-demographic characteristics of the study participants in seven regional states across Ethiopia.</li> <li><b>Distribution of the Duffy genotypes and prevalence of gametocyte across Ethiopia</b> Of the 447 study participants, 422 (94.4%) were confirmed with <i>Plasmodium</i> infections.</li> <li>About 72% of the cases were <i>P. vivax</i> infection (322 out of 447), 1.8% were <i>P. falciparum</i> infection (8 out of 447), and 20.6% were <i>P. vivax-P. falciparum</i> mixed infection (92 out of 447).</li> </ul>

186	Duffy-negatives were infected with <i>P. vivax</i> , five (5/20) were infected with both <i>P. vivax</i> and <i>P.</i>
187	falciparum, and four (4/20) were not infected. Duffy-negative infections by P. vivax were
188	observed in different sites across Ethiopia, specifically in the Amhara, Oromia,
189	Benishangul/gumuz and SNNPR regions but not in Afar, Gambella, and Sidama regions. This
190	could be due to the small sample size in these study sites.
191	The gametocyte prevalence in Duffy-negative individuals was 31.3% (5 out of 16), with
192	one of them detected in a P. vivax-P. falciparum mixed infection. This proportion had no
193	significant difference from Duffy-positive samples which showed 37.7% (150 out of 398), with
194	26 of them detected in P. vivax-P. falciparum mixed infections. Gametocyte stages of P. vivax
195	infections were mostly found in the SNNPR, 46.2% (70 out of 155) and Amhara, 30.3% (47 out
196	of 155) followed by Oromia, 12.9% (20 out of 155). There was no gametocyte detected in P.
197	falciparum infections. Five gametocyte-positive P. vivax infections were detected in Duffy-
198	negatives including two from Amhara, two from SNNPR, and one from Oromia regions (Table
199	2).
200	<b>Table 2.</b> Distribution of the Duffy genotypes among <i>Plasmodium</i> species infections, mixed ( <i>Pf</i>
201 202	and $Pv$ ) infections, and gametocyte carriers across Ethiopia.
203	Asexual parasitemia and parasite stage comparisons
204	No significant difference was detected in parasitemia among the <i>P. vivax</i> samples
205	collected from southwestern, southern, and eastern regions of Ethiopia, except for samples in
206	Amhara, which is in the northwest. While previous studies indicated that parasitemia in Duffy-
207	negative individuals are expected to be low, our data showed that <i>P. vivax</i> parasitemia in Duffy
208	negatives widely vary among infections, with relatively low parasitemia observed in Oromia and
209	SNNPR regions (Figure 2).

- Figure 2. Asexual parasitemia comparison by qPCR among Duffy-positive and Duffy-negative
  malaria patients in different major regions of Ethiopia.
- 212
- 213 Most of the infections had mixed parasite stages and the proportion of parasite stages vary
- among regions. In SNNPR, 71 out of 140 (50.7%) *P. vivax* samples had trophozoites, 66 (47.1%)
- with mixed trophozoite, schizont, and gametocyte stages, and three (2.1%) with gametocytes
- only. In Oromia, 99 of the 118 (83.9%) *P. vivax* samples had trophozoites, followed by 16
- 217 (13.6%) with mixed trophozoite, schizont, and gametocyte stages, and three (2.5%) with
- 218 gametocytes only. In Amhara, similar proportion was observed where 55 of 107 (51.4%) *P. vivax*
- samples had mixed trophozoite, schizont, and gametocyte stages, followed by 45 (42.1%) with
- trophozoites, and three (2.8%) with gametocytes. In Benshangul/gumuz, 17 of 22 (77.3%) P.
- 221 vivax samples had trophozoites and five (22.7%) had mixed trophozoite, schizont, and
- 222 gametocytes. In Gambella, 11/15 (73.3%) *P. vivax* samples had trophozoites with gametocyte
- 223 mixed and gametocyte only. In Afar, all five mixed *P. vivax* and *P. falciparum* samples were
- detected trophozoites. In Sidama, the two *P. vivax* samples had mixed trophozoite, schizont, and
- gametocyte stages. Overall, almost all samples had trophozoites and mixed stages across studysites (Figure 3).
- Figure 3. Comparison of parasite stages of *P. vivax*-infected samples by microscopic
  examination across broad regions of Ethiopia.
- 229
- The gametocyte count of *P. vivax* species was done with a light microscope against 200
  WBCs and calculated using an average WBC count value per µl of blood. The highest
  gametocyte count was 2856 gametocyte/µl, detected in homozygous Duffy-negative individual
  and the lowest gametocyte count was 15 gametocytes/µl, detected in heterozygous Duffy-

It is made available under a CC-BY-NC-ND 4.0 International license .

234 positive individual. The average number of *P. vivax* gametocyte stages among all samples

detected with gametocyte stages and all Duffy blood group status was 449 gametocytes/µl of

blood, of which the average gametocyte counts of homozygous Duffy negatives (CC),

heterozygous Duffy positives (TC) and homozygous Duffy positives (TT) were 1060

238 gametocytes/µl, 425 gametocytes/µl and 395 gametocytes/µl, respectively (Figure 4).

Figure 4. The gametocyte counts among homozygous Duffy-negatives (CC), heterozygous

240 Duffy-positives (TC) and homozygous Duffy-positives (TT) isolates of *P. vivax* species.

241

## 242 Duffy blood group and other factors associated with *Plasmodium* infections

243 The bivariate analysis was done to show the association of *P. vivax* infection with 244 independent factors. The prevalence of *P. vivax* infections in Duffy positive individuals were 245 about four times more likely than the Duffy negatives (OR = 4.6, 95% CI 1.4, 14.96, p = 0.011). 246 P. vivax infection was not significantly different among males and females. Although the 247 prevalence of *P. vivax* infection was recorded in all age groups, a relatively higher in the age 248 group < 15 years old, three times more likely than the age group > 45 years old (OR = 2.9, 95%) 249 CI 0.45-1.98, p = 0.98). The *Plasmodium* infections were significantly different among various 250 clinical symptoms of the study participants. The odds of infection among patients with headache 251 was three times more likely than without headache (OR = 3.0, 95% CI 0.81-11.14, p = 0.09), 252 patients who had sweating is three times more likely than those who did not have sweating (OR 253 = 3.5, 95% CI 1.7-7.44, p = 0.0009) and among patients with chills were over two times more 254 likely than without chills (OR = 2.5, 95% CI 1.05-4.8, p = 0.037). No significant difference was 255 found in malaria symptoms such as fever, muscle and joint pain, nausea, and vomiting between 256 plasmodium infected and non-infected individuals (p > 0.05) (**Table 3**).

Table 3. Results of bivariate odds ratio to determine main predictors of *Plasmodium* infections
 across Ethiopia. Asterisk represents significance at level of 0.05.

It is made available under a CC-BY-NC-ND 4.0 International license .

259

#### 260 **Discussion**

261 In Sub-Saharan Africa where Duffy-negative individuals are predominant, vivax malaria 262 has been reported but whether these infections can transmit among individuals is poorly 263 documented. This study indicates that *P. vivax* infections in Duffy-negative individuals distribute 264 across broad regions of Ethiopia. In our study, the prevalence of *P. vivax* among Duffy-negatives 265 was 3.8% (16/421). The result is in line with previous studies in the country revealed the prevalence of *P. vivax* among Duffy-negatives  $2.9\%^{32}$  and 4.4%, <sup>33</sup> on the contrary our result is 266 lower than the result found in Sudan (17.9).<sup>34</sup> In the general populations, Duffy negativity varies 267 from 20–36% in East Africa to 84% in Southern Africa.<sup>4</sup> Compared to Duffy-positive infections, 268 the average parasite density is much lower in Duffy-negative infections.<sup>4</sup> Nonetheless, a few 269 270 Duffy-negative P. vivax infections in Amhara were detected with relatively high parasitemia, 271 suggestive of certain *P. vivax* strains can invade Duffy-negative erythrocytes efficiently. The 272 exact mechanisms of Duffy-negative erythrocyte invasion by *P. vivax* are still unclear and merit 273 further investigation. For instance, *P. vivax* glycosylphosphatidylinositol-anchored micronemal 274 antigen (PvGAMA) and merozoite surface protein-1 paralog (PvMSP1P) have been recently 275 shown to bind to both Duffy-positive and negative red blood cells, suggesting their possible involvement in Duffy-independent invasion pathway.<sup>35-37</sup> The reticulocyte binding protein 276 277 (PvRBP2b) of P. vivax has been shown to bind to transferrin receptor 1 (TfR1) to invade Duffypositive RBCs and thus, present alternative pathways for Duffy-negative erythrocyte invasion.<sup>5,38</sup> 278 Such findings are critical to the development of blood-stage vaccine against the parasites.<sup>39-41</sup> 279 280 Amongst regions, the difference in *P. vivax* gametocyte production in Duffy-positive and 281 Duffy-negative individuals was not significant. However, the mean number of gametocyte count

282	among Duffy-negatives was higher compared to Duffy-positives, 1060 gametocytes/ $\mu$ l and 425
283	gametocytes/ $\mu$ l, respectively. This result indicates the dominance of sexual stages of <i>P. vivax</i>
284	parasites that contributes for the occurrence of asymptomatic infections in Duffy-negative
285	individuals. The detection of <i>P. vivax</i> gametocytes in Duffy-negative infections in Amhara,
286	Oromia, and SNNPR raises concern that these infections not only cause clinical symptoms but
287	can also contribute to transmission, despite its lower prevalence than in Duffy-positive infected
288	individuals. Given Duffy-negative and Duffy-positive individuals co-exist in Ethiopia, the extent
289	of transmission remains uncertain. It is possible that the asexual parasites converted into
290	gametocytes and spread from Duffy-negative to other Duffy-negative or Duffy-positive
291	individuals. <sup>4,32,42</sup> This finding lends support to earlier study showing that the parasites detected in
292	Duffy-negative and Duffy-positive populations were not genetically different. <sup>4</sup> Based on
293	computation modeling, Duffy-negatives in Ethiopia can serve as both the source and sink of
294	infections, though transmission is likely more frequent in Duffy-positives. <sup>4,5</sup>
295	Given that <i>P. vivax</i> has been widely reported in West and Central Africa where $> 90\%$ of
296	the populations are Duffy-negatives, these infections can certainly serve as reservoirs for
297	transmission both at the local and regional level. <sup>5,33</sup> Due to previously being exposed, the host
298	may have acquired immunity against symptomatic blood-stage parasitemia; however, due to the
299	early gametocyte development of P. vivax, long lasting sub-clinical illnesses may still contribute
300	to continuous transmission. <sup>43,44</sup> In this study, almost all gametocytes detected among the mixed
301	infections were P. vivax. This result supports the notion that the development of P. vivax
302	gametocytes is much faster than the P. falciparum ones at the onset of symptoms in febrile
303	malaria patients, and that P. falciparum gametocytes are seldomly detected in routine
304	microscopic examination of febrile malaria patients. <sup>45</sup>

It is made available under a CC-BY-NC-ND 4.0 International license .

305 Most *P. vivax* infections in Amhara, Gambella, Sidama, and SNNPR had mixed parasite 306 stages including gametocytes, whereas in Oromia and SNNPR, trophozoites were prominent in 307 most samples. This variation in the parasite developmental stages could be associated with 308 environmental, host and parasite factors among different study districts. The epidemiology of 309 malaria within each district may also be a determining factor. For instance, while the general 310 proportion of *P. falciparum* and *P. vivax* in Ethiopia is 60% and 40%, respectively, considerable 311 regional difference exists.<sup>46</sup>

312 Warmer temperatures and higher rainfall/humidity in lowland than highland areas may 313 allow parasites to develop faster and greater production of gametocytes, which result in majority 314 mixed stages among *P. vivax* infections and enhance transmission. This might be supported by 315 the ability of the parasite to develop the asexual stage into gametocytes faster, within 48 hours 316 after generation of the first merozoites in the blood. The *P. vivax* infected and swollen RBCs due 317 to gametocyte development are flexible and can pass splenic filtration helps to stay all stages together in the peripheral blood.<sup>13</sup> The unique biological features and genetic variability of the *P*. 318 *vivax* parasites certainly present a challenge in eradicating malaria in Ethiopia.<sup>47,48</sup> 319

For all *P. vivax* confirmed infections, typical symptoms were fever as well as headache and fatigue. Other symptoms including muscle and joint pain, chills, sweating, and vomiting vary by individuals across the seven study regions. Interestingly, our analyses revealed that *P. vivax* cases were more likely to occur in individuals aged  $\leq 15$  years old followed by < 45 and >15 years old age group. Such demographic pattern could be explained as the host immunity in old individuals might be higher compared to the younger and children. The mosquito vector feeding time and behavior (outdoor or indoor resting/biting), the form of occupation (outdoor or

It is made available under a CC-BY-NC-ND 4.0 International license .

327 indoor), environment (rural or remote populations), and economic status (poverty) also have contribution.<sup>49</sup> These factors are critical when identifying disease trends or at-risk population.<sup>5</sup> 328 329 To conclude, the prevalence of Duffy-negative individuals among *P. vivax* malaria 330 patients varies across Ethiopia. This study confirms that Duffy-negativity does not completely 331 protect against *P. vivax* infection and these infections are frequently associated with low 332 parasitemia, which may represent hidden reservoirs that can contribute to transmission. 333 Understanding *P. vivax* transmission biology and gametocyte function via infectivity studies and 334 *in vitro* assays especially in Duffy-negative populations would enhance the treatment and control 335 strategies of vivax malaria in Africa. Further study is needed to quantify Pvs25 transcripts by 336 qRT-PCR for gametocyte density in Duffy-negative infected samples and to expand sample size 337 that will allow fair comparisons of gametocyte carriage between Duffy-positive and Duffy-338 negative infections. A deeper comprehension of the association between Duffy-negativity and 339 the invasion processes of *P. vivax* would aid the development of *P. vivax* specific eradication 340 tactics, including substitute antimalarial immunizations other than a Duffy-binding protein-based 341 vaccine.

342

#### 343 Acknowledgements

We thank the laboratory staffs at each sample collection health facilities for assisting sample collection and preliminary laboratory work; Adama malaria center expert microscopists for microscopic examinations; and all study participants for their willingness to provide blood sample and information. We also thank Alfred Hubbard for creating the map for Figure 1.

348

349 Funding

It is made available under a CC-BY-NC-ND 4.0 International license .

350	This research is supported by NIH R01 AI162947 and R01 AI173171.
351	Disclosure: The study was conducted with permission from the institutional scientific and ethical
352	review boards of Ethiopian Public Health Institute, Ethiopia and Drexel University, USA.
353	Written informed consent/assent for study participation was obtained from all participants.
354	
355	All data produced in the present study are available upon reasonable request made to the
356	corresponding author, as per institutional and national legal norms and procedures.
357	
358	Authors' contributions
359	TTS, EL, SM and EL Conceptualization and designed the study; TTS, MTN, and AA collected
360	sample and perform preliminary laboratory tests; EL, BRA and EL performed molecular
361	laboratory test, analysis, and interpretation; TTS, EL, BRA, JP and EL wrote and reviewed the
362	paper. All authors read and approved the final manuscript.
363	
364	Authors' addresses: Ebony Little, Department of Biological Sciences, University of North
365	Carolina at Charlotte, North Carolina, USA, e-mail: <u>elittle23@charlotte.edu</u> . Tassew T.
366	Shenkutie, Beka R. Abagero, and Eugenia Lo, Department of Microbiology and Immunology,
367	Drexel University, College of Medicine, Philadelphia, PA, USA, e-mails: ts3576@drexel.edu,
368	bra38@drexel.edu, and el855@drexel.edu. Meshesha Tsigie Negash, Abnet Abebe, and Sindew
369	Mekasha, Ethiopian Public Health Institute, Addis Ababa, Ethiopia, e-mails:
370	meshye21@gmail.com, abnetabas@gmail.com, and mekashasindeaw@yahoo.com. Jean
371	Popovici, Institute Pasteur in Cambodia, Phnom Penh, Cambodia, e-mail: jpopovici@pasteur-
372	<u>kh.org</u> .
373	
374	Reference
375	1. Organization WH. <i>World malaria report 2022</i> : World Health Organization, 2022.

376 2. Menkin-Smith. Winders, Plasmodium vivax malaria. *Statepearls* 2022.

It is made available under a CC-BY-NC-ND 4.0 International license .

377 Golassa L, Amenga-Etego, L., Lo, E., Amambua-Ngwa, A. The biology of unconventional 3. 378 invasion of Duffy-negative reticulocytes by Plasmodium vivax and its implication in malaria 379 epidemiology and public health. *Malar J* 2020; 19:299. 380 4. Lo E, et al.,. Contrasting epidemiology and genetic variation of Plasmodium vivax 381 infecting Duffy-negative individuals across Africa. Int J Infect Dis 2021;108:63-71. 382 Popovici J, C. Roesch, and V. Rougeron. The enigmatic mechanisms by which Plasmodium 5. 383 vivax infects Duffy-negative individuals. PLos Pathogens 2020;16. 384 Abagero BR, Rama R, Obeid A, et al. Detection of Duffy Blood Group Genotypes and 6. 385 Submicroscopic Plasmodium Infections Using Molecular Diagnostic Assays in Febrile Malaria 386 Patients. 2023. 387 Ménard D, et al.,. Plasmodium vivax clinical malaria is commonly observed in Duffy-7. 388 negative Malagasy people. Proc Natl Acad Sci U S A 2010;107:5967-5971. 389 Baird JK. African Plasmodium vivax malaria improbably rare or benign. Trends in 8. 390 Parasitology 2022;38:683-696. 391 9. Ford A, Kepple, D., Williams, J., Kolesar, G., Ford, C. T., Abebe, A., Golassa, L., Janies, D. 392 A., Yewhalaw, D., Lo, E. Gene Polymorphisms Among Plasmodium vivax Geographical Isolates 393 and the Potential as New Biomarkers for Gametocyte Detection. Front Cell Infect Microbiol 394 2021;11:789417. 395 Venugopal K, Hentzschel, F., Valkiūnas, G., Marti, M. Plasmodium asexual growth and 10. 396 sexual development in the haematopoietic niche of the host. Nat Rev Microbiol 2020;18:177-397 189. 398 Wang Q, H. Fujioka, and V. Nussenzweig, Exit of Plasmodium sporozoites from oocysts is 11. 399 an active process that involves the circumsporozoite protein. *PLoS Pathog* 2005;1:e9. 400 Rossati A, Bargiacchi, O., Kroumova, V., Zaramella, M., Caputo, A., Garavelli, P. L. Climate, 12. 401 environment and transmission of malaria. Infez Med 2016;24:93-104. 402 Alemayehu A. Biology and epidemiology of Plasmodium falciparum and Plasmodium 13. vivax gametocyte carriage: Implication for malaria control and elimination. Parasite Epidemiol 403 404 Control 2023;21:e00295. 405 14. Meibalan E, Marti M. Biology of Malaria Transmission. Cold Spring Harb Perspect Med 406 2017;7. 407 Shenkutie TT, Nega D, Hailu A, et al. Prevalence of G6PD deficiency and distribution of its 15. 408 genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern 409 Ethiopia. Malaria Journal 2022;21:1-10. 410 Tachibana M, Takashima, E., Morita, M., Sattabongkot, J., Ishino, T., Culleton, R., Torii, M., 16. 411 Tsuboi, T. Plasmodium vivax transmission-blocking vaccines: Progress, challenges and 412 innovation. Parasitol Int 2022;87:102525. 413 17. Takashima E, Tachibana, M., Morita, M., Nagaoka, H., Kanoi, B. N., Tsuboi, T. 414 Identification of Novel Malaria Transmission-Blocking Vaccine Candidates. Front Cell Infect 415 Microbiol 2021;11:805482.

- 416 18. URL Afar-assaita geographic coordinates.
- 417 19. URL. Amhara, Ethiopia geographic information.
- 418 20. URL. GPS coordinate of Gambella, Ethiopia.
- 419 21. URL. GPS coordinate of Oromia region, Ethiopia.
- 420 22. URL. GPS coordinate of Sidama, Ethiopia.

It is made available under a CC-BY-NC-ND 4.0 International license .

421 URL. GPS coordinate of SNNPR, Ethiopia. 23. 422 24. Santana-Morales MA, Afonso-Lehmann, R. N., Quispe, M. A., Reyes, F., Berzosa, P., Benito, A., Valladares, B., Martinez-Carretero, E. Microscopy and molecular biology for the 423 424 diagnosis and evaluation of malaria in a hospital in a rural area of Ethiopia. *Malar J* 2012;11:199. 425 Weiland AS. Recent Advances in Imported Malaria Pathogenesis, Diagnosis, and 25. 426 Management. Curr Emerg Hosp Med Rep 2023;11:49-57. 427 Walsh PS, D.A. Metzger, and R. Higuchi. Chelex 100 as a medium for simple extraction of 26. 428 DNA for PCR-based typing from forensic material. *Biotechniques* 1991;10:506-513. 429 27. Johnston SP, Pieniazek, N. J., Xayavong, M. V., Slemenda, S. B., Wilkins, P. P., da Silva, A. J. 430 PCR as a confirmatory technique for laboratory diagnosis of malaria. J Clin Microbiol 431 2006;44:1087-1089. 432 28. Xu W, Morris, U., Aydin-Schmidt, B., Msellem, M. I., Shakely, D., Petzold, M., Björkman, 433 A., Mårtensson, A. SYBR Green real-time PCR-RFLP assay targeting the plasmodium cytochrome 434 B gene--a highly sensitive molecular tool for malaria parasite detection and species 435 determination. PLoS One 2015;10:e0120210. 436 Dieng CC, Gonzalez, L., Pestana, K., Dhikrullahi, S. B., Amoah, L. E., Afrane, Y. A., Lo, E. 29. 437 Contrasting Asymptomatic and Drug Resistance Gene Prevalence of Plasmodium falciparum in 438 Ghana: Implications on Seasonal Malaria Chemoprevention. Genes (Basel) 2019;10. 439 30. URL. QuantStudio<sup>™</sup> 3 Real-Time PCR System, 96-well, 0.2 mL. 440 31. Ahmed S, et al.,. Prevalence and distribution of Plasmodium vivax Duffy Binding Protein 441 gene duplications in Sudan. PLoS One 2023;18:e0287668. 442 Abate A, Bouyssou, I., Mabilotte, S., Doderer-Lang, C., Dembele, L., Menard, D., Golassa, 32. 443 L. Vivax malaria in Duffy-negative patients shows invariably low asexual parasitaemia: 444 implication towards malaria control in Ethiopia. *Malar J* 2022;21:230. 445 33. Abebe A, Bouyssou, I., Mabilotte, S., Dugassa, S., Assefa, A., Juliano, J. J., Lo, E., Menard, 446 D., Golassa, L. Potential hidden Plasmodium vivax malaria reservoirs from low parasitemia 447 Duffy-negative Ethiopians: Molecular evidence. PLoS Negl Trop Dis 2023;17:e0011326. 448 Albsheer MMA, Pestana, K., Ahmed, S., Elfaki, M., Gamil, E., Ahmed, S. M., Ibrahim, M. 34. 449 E., Musa, A. M., Lo, E., Hamid, M. M. A. Distribution of Duffy Phenotypes among Plasmodium 450 vivax Infections in Sudan. Genes (Basel) 2019;10. 451 Han JH, et al. Plasmodium vivax Merozoite Surface Protein 1 Paralog as a Mediator of 35. 452 Parasite Adherence to Reticulocytes. Infect Immun 2018;86. 453 Han JH, et al. Inhibition of parasite invasion by monoclonal antibody against epidermal 36. 454 growth factor-like domain of Plasmodium vivax merozoite surface protein 1 paralog Sci Rep 455 2019;9. 456 37. Cheng Y, et al. Plasmodium vivax GPI-anchored micronemal antigen (PvGAMA) binds 457 human erythrocytes independent of Duffy antigen status. Sci Rep 2016. 458 38. Kanjee U, et al. Plasmodium vivax Strains Use Alternative Pathways for Invasion. J Infect 459 Dis, 2021;223:1817-1821. 460 Popovici J, Roesch, C., Carias, L. L., Khim, N., Kim, S., Vantaux, A., Mueller, I., Chitnis, C. 39. 461 E., King, C. L., Witkowski, B. Amplification of Duffy binding protein-encoding gene allows 462 Plasmodium vivax to evade host anti-DBP humoral immunity. Nat Commun 2020; 11:953. 463 40. Rawlinson TA, et al. Structural basis for inhibition of Plasmodium vivax invasion by a 464 broadly neutralizing vaccine-induced human antibody. Nat Microbiol, 2019;4:1497-1507.

465	41. Urusova D, et al. Author Correction: Structural basis for neutralization of Plasmodium
466	vivax by naturally acquired human antibodies that target DBP. Nat Microbiol, 2019;4:2024.
467	42. Kepple D, et al. Plasmodium vivax From Duffy-Negative and Duffy-Positive Individuals
468	Share Similar Gene Pools in East Africa. J Infect Dis, 2021;224:1422-1431.
469	43. Bantuchai S, H. Imad, and W. Nguitragool. Plasmodium vivax gametocytes and
470	transmission. Parasitology International 2022;87.
471	44. Howes RE, et al. Plasmodium vivax Transmission in Africa. <i>PLoS Negl Trop Dis</i> 2015;9.
472	45. de Jong RM, Tebeje, S. K., Meerstein-Kessel, L., Tadesse, F. G., Jore, M. M., Stone, W.,
473	Bousema, T. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax
474	parasites. Immunol Rev 2020;293:190-215.
4/5 176	46. Nega D, et.al. Baseline malaria prevalence at the targeted pre-elimination districts in
470 477	A7 Habtamu K Petros B. Van G. Plasmodium vivay: the notential obstacles it presents to
478	malaria elimination and eradication. Tron Dis Travel Med Vaccines 2022.8
479	48. Benavente ED. et al. Distinctive genetic structure and selection patterns in Plasmodium
480	vivax from South Asia and East Africa. <i>Nat Commun</i> 2021;12:3160.
481	49. Abagero BR, et al. Low Density Plasmodium Infections and G6PD Deficiency Among
482	Malaria Suspected Febrile Individuals in Ethiopia. Front Trop Dis 2022;3.
483	
484	
485	
486	
487	
488	
489	
490	
491	
492	
493	
494	
495	
496	
497	
498	
499	
500	

It is made available under a CC-BY-NC-ND 4.0 International license .

## **Table 1.** Socio-demographic characteristics of the study participants in seven regional states

## 502 across Ethiopia.

Characteristics		Number of participants (%)
Gender		
	Male	269 (60.1%)
	Female	171 (38.2%)
Age (years old)		
	< 15	150 (33.5%)
	$\geq 16$ and $< 45$	273 (61.0%)
	$\geq$ 45	16 (3.5%)
Region		
	Afar	5 (1.1%)
	Amhara	107 (23.9%)
	Benishangual/Gumuz	22 (4.9%)
	Gambella	15 (3.3%)
	Oromia	140 (31.3%)
	Sidama	2 (0.4%)
	SNNPR	156 (34.8%)

# 514 **Table 2.** Distribution of the Duffy genotypes among *Plasmodium* species infections, mixed (*Pf* and *Pv*) infections, and gametocyte 515 carriers across Ethiopia.

Region	Total samples			Du	ffy-positives	5			Duf	fy-negatives	
		Pv	<b>P</b> f	Mixed Pv-Pf	Malaria- negative	Pv with gametocytes	Pv	Pf	Mixed Pv-Pf	Malaria- negative	Pv with gametocytes
Afar	5	0	0	5	0	0	0	0	0	0	0
Amhara	107	65	4	18	15	45	5	0	0	0	2
Benishangul/Gumuz	22	6	0	13	0	5	2	0	0	1	0
Gambella	15	7	0	8	0	11	0	0	0	0	0
Oromia	140	116	3	13	1	19	3	0	2	3	1
Sidama	2	2	0	0	0	2	0	0	0	0	0
SNNPR	156	120	0	26	6	68	1	0	3	0	2
Total	447	315	7	83	22	150	11	0	5	4	5

- 517
- 518 **Table 3.** Results of bivariate odds ratio to determine main predictors of *Plasmodium* infections
- 519 across Ethiopia. Asterisk represents significance at level of 0.05.

Parameters		Infection rate by 18s qPCR				
		Total	Infection	Non-	Odds ratio (95% CI)	
		samples		infection		
Duffy	Duffy+	427	405	22	4.6 (1.4, 14.96), <i>P</i> = 0.011*	
status	Duffy-	20	16	4	1	
Gender	Female	171	159	12	1	
	Male	269	249	20	0.94 (0.45, 1.98) <i>P</i> = 0.87	
Age (years	≤ 15	150	143	7	2.9 (0.55, 15.4) <i>P</i> = 0.21	
old)	> 15 and < 45	273	250	23	1.55 (0.33, 7.26) <i>P</i> = 0.58	
	≥ 45	16	14	2	1	
Symptoms						
Fever	Yes	398	369	29	0.59 (0.03, 10.43) <i>P</i> = 0.72	
	No	10	10	0	1	
Headache	Yes	391	365	26	3.0 (0.81-11.14) <i>P</i> =0.099	
	No	17	14	3	1	
Fatigue	Yes	257	238	19	0.89 (0.4, 1.96) <i>P</i> =0.77	
	No	151	141	10	1	
Muscle and	Yes	257	240	17	1.12 (0.52, 2.41) <i>P</i> = 0.77	
Joint Pain	No	163	151	12	1	
Chills	Yes	258	245	13	2.25 (1.05, 4.8) <i>P</i> =0.037*	
	No	150	134	16	1	

It is made available under a CC-BY-NC-ND 4.0 International license .

Sweating	Yes	218	208	10	3.5 (1.7, 7.44) <i>P</i> = 0.0009*
	No	200	171	29	1
Nausea and	Yes	177	163	14	0.81 (0.38, 1.73) <i>P</i> =0.59
Vomiting	No	230	215	15	1

520

It is made available under a CC-BY-NC-ND 4.0 International license .



**Figure 1.** A map showing the study sites in Ethiopia with malaria incidence ranges from high in the western part to low in the eastern part of the country. These sites represent seven major regions including Afar, Amhara, Benishangul/Gumuz, Gambella, Oromia, Sidama, and Southern Nations, Nationalities, and People's Region (SNNPR) with diverse ethnic groups.



**Figure 2.** Asexual parasitemia comparison by qPCR among Duffy-positive and Duffy-negative malaria patients in different major regions of Ethiopia.



**Figure 3.** Comparison of parasite stages of *P. vivax*-infected samples by microscopic examination across broad regions of Ethiopia.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 4. The gametocyte counts among homozygous Duffy-negatives (CC), heterozygous

Duffy-positives (TC) and homozygous Duffy-positives (TT) isolates of P. vivax species.